Immunotherapy News and Research

Latest Immunotherapy News and Research

Targeted therapy combination shows superior outcomes in advanced kidney cancer

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney cancer – whose disease progressed following immunotherapy.

18 Oct 2025

CRATERs identified as key sites for T cell-mediated tumor destruction

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing. These craters could serve as good markers for immunotherapy success.

17 Oct 2025

Research reveals how immune cells orchestrate the release of toxic granules

When immune cells strike, precision is everything. New research reveals how natural killer and T cells orchestrate the release of toxic granules – microscopic packages that destroy virus-infected or cancerous cells.

17 Oct 2025

Thymic health found to predict immunotherapy success in cancer patients

The health of the thymus - a key part of the body's immune system - is associated with cancer patients' outcomes to immune checkpoint inhibitor treatment, according to a ground-breaking international study reported at ESMO 2025.

16 Oct 2025

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

15 Oct 2025

Study explores how losing the Y chromosome fuels bladder cancer aggressiveness

University of Arizona Cancer Center researchers will study the potential effects of the loss of the Y chromosome in the development and progression of bladder cancer thanks to a grant of up to $6.5 million over seven years from the National Cancer Institute.

14 Oct 2025

Scalable synthetic biology revolutionizes targeted therapy with logic-gate proteins

Targeted drug delivery is a powerful and promising area of medicine. Therapies that pinpoint the exact areas of the body where they're needed - and nowhere they're not - can reduce the medicine dosage and avoid potentially harmful "off target" effects elsewhere in the body.

10 Oct 2025

Nanoparticle vaccine shows promise in preventing multiple cancers in mice

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic and triple-negative breast cancer in mice.

9 Oct 2025

UCSF team uncovers breakthrough immunotherapy for colon cancer liver metastases

Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to the liver.

8 Oct 2025

Repeated sampling offers insight into glioblastoma therapy response

A multi-institutional study from the Accelerating GBM Therapies Through Serial Biopsies TeamLab, led by investigators from the Mass General Brigham Cancer Institute, found that serially testing tumor samples can help detect when a cancer treatment is activating the immune system in recurrent glioblastoma (GBM), even when traditional imaging measures cannot.

8 Oct 2025

Nanomedicine emerges as a key tool to boost cancer immunotherapy

Scientists at the Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging trends in cancer immunotherapy, with back-to-back review articles published in Nature Cancer and Trends in Cancer that look at how nanotechnology could reprogram the immune system and help overcome tumors' defenses.

8 Oct 2025

Engineered Salmonella therapy delivers immune payloads to combat cancer

A new research paper was published in Volume 16 of Oncotarget on October 6, 2025, titled "ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response."

8 Oct 2025

Engineered CAR-NK cells show enhanced cancer killing and immune evasion

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.

8 Oct 2025

Moffitt awarded $22.4 million grant to lead novel studies and clinical trials for leptomeningeal disease

Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead groundbreaking studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.

6 Oct 2025

Newly discovered mechanism helps leukemia cells to evade the immune system

A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system.

3 Oct 2025

Deadly brain cancer erodes skull bone and alters immune marrow

Scientists at Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have shown for the first time that glioblastoma-the deadliest form of brain cancer-affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and interferes with the body's immune response.

3 Oct 2025

Engineered CAR T cells show promise against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers.

2 Oct 2025

Early trial finds promise for avelumab and radiation in treating leptomeningeal disease

Researchers at Moffitt Cancer Center have reported encouraging results from a phase 1B clinical trial showing that the immunotherapy drug avelumab, when combined with whole brain radiotherapy, may provide a safe and effective treatment option for patients with leptomeningeal disease, one of the most aggressive and difficult-to-treat complications of advanced cancer.

30 Sep 2025

Boosting the immune system to prevent cancer recurrence and improve survival

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children's Hospital report new evidence that a novel means of boosting the natural immune system prevents cancer recurrence and improves survival.

30 Sep 2025

New 'GLed' tool enables real-time monitoring of T cell activity

The new 'GLed' tool, unique in its reversibility, allows the functional state of T cells to be observed for the first time, representing a crucial advance in personalizing treatments in immunotherapy, transplants, and autoimmune diseases.

30 Sep 2025